SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

Impact · against what's priced in

The news is marginally negative for ARS Pharmaceuticals as it introduces a new legal overhang regarding neffy's commercialization timeline. For Alibaba, the news is a non-event as the market has already fully priced in the ongoing securities class action lawsuits.

BABA+0.00

Already priced in

The price assumes

The ongoing securities class action lawsuit alleging undisclosed affiliation with the Chinese Ministry of Industry and Information Technology.